RDCs Revolutionize Cancer Care with Integrated Diagnosis and Therapy

Radionuclide drug conjugates (RDCs) are emerging as groundbreaking agents that combine diagnosis and therapy into a single clinical workflow, potentially transforming cancer treatment. By linking radioactive isotopes with antibodies, peptides, or small molecules, these innovative compounds enable precise tumor targeting, high diagnostic sensitivity, and effective localized radiotherapy. A comprehensive review published in the Medical Journal of Peking Union Medical College Hospital in July 2025 provides an in-depth analysis of 15 years of progress in RDC research, conducted by a team from Peking Union Medical College Hospital. The study summarizes current RDC classifications, clinical development trends, and supportive policy frameworks, highlighting the expanding number of clinical trials, new therapeutic targets, and national-level guidance that are shaping the next generation of precision radiopharmaceuticals.

Structurally, RDCs are categorized into antibody-, peptide-, and small-molecule–based conjugates, each offering unique pharmacological advantages. The review emphasizes the rise of cyclic peptide conjugates, which exhibit low toxicity and high tumor selectivity. Policy reforms—including technical guidelines issued by regulatory agencies since 2020—have standardized clinical evaluation, non-clinical research, and radiochemical quality control, creating a more predictable environment for innovation. As noted by Prof. Hongyun Wang, senior author of the review, "RDCs represent the only class of therapeutics capable of achieving true integration of diagnosis and treatment." Despite challenges in radiochemical synthesis, stability, and regulatory alignment, the field is witnessing unprecedented enthusiasm and cross-disciplinary collaboration.

RDCs hold vast potential to transform cancer management by enabling simultaneous imaging, treatment, and response monitoring within a single platform. With aging populations and rising cancer incidence, demand for next-generation radiopharmaceuticals is growing. The review underscores the need for stronger innovation capacity, improved isotope supply chains, and streamlined approval processes to support RDC translation from laboratory to clinic. Through coordinated scientific, industrial, and regulatory efforts, RDCs are expected to become a central component of future oncology care, offering patients more accurate diagnoses and safer, more effective treatment pathways. For more details, visit the Medical Journal of Peking Union Medical College Hospital and explore related information at Chuanlink Innovations.